New Antiseizure Drugs on the WayNew Antiseizure Drugs on the Way
Extended-release topiramate should be available soon, with intravenous midazolam also being investigated. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 24, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Carey Danis & Lowe Imparts Legal Expertise Following $11 Million...
A national law firm providing pharmaceutical litigation services, Carey Danis & Lowe shares their expert legal opinion on the future of Topamax cases.(PRWeb December 18, 2013)Read the full story at http://www.prweb.com/releases/carey-danis-lowe/topamax-lawsuit-verdict/prweb11421347.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 20, 2013 Category: Pharmaceuticals Source Type: news
Jannsen Ordered to Pay $11 Million in Topamax Birth Defects Case: Now,...
According to Bloomberg (11/19/13), a Philadelphia jury ordered J&J's Janssen to pay $11 million in a case claiming that Topamax caused birth defects. In light of this news, AttorneyOne, a...(PRWeb December 06, 2013)Read the full story at http://www.prweb.com/releases/2013/12/prweb11396783.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 7, 2013 Category: Pharmaceuticals Source Type: news
Qsymia Trims Sleep Apnea as Well as Weight (CME/CE)
ATLANTA (MedPage Today) -- Obese patients treated with the weight-loss combination of phentermine plus topiramate (Qsymia ER) for 28 weeks lost significant amounts of weight and also saw relief from their obstructive sleep apnea, researchers found. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 15, 2013 Category: Endocrinology Source Type: news
Janssen Must Pay $4 Million in Topamax Birth Defects Lawsuit: Now,...
As Businessweek reported on October 30, a Philadelphia jury said that J&J's Janssen must pay $4 million in a lawsuit claiming that Topamax caused birth defects. In light of this news,...(PRWeb November 05, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11297266.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 5, 2013 Category: Pharmaceuticals Source Type: news
Epilepsy, migraine medication treats cocaine dependence
BALTIMORE, Oct. 29 (UPI) -- The drug topiramate, used to treat epilepsy and migraines, is a safe and efficacious medicine for the treatment of cocaine dependence, U.S. researchers say. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 30, 2013 Category: Consumer Health News Source Type: news
Combo Drug Qsymia Tops for Weight Loss
(MedPage Today) -- Overweight people who took the phentermine/topiramate combination diet drug Qsymia lost more weight than people taking a placebo or either drug alone in an industry-funded study. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - October 29, 2013 Category: Pediatrics Source Type: news
Anticonvulsant May Help Treat Cocaine AddictionAnticonvulsant May Help Treat Cocaine Addiction
Topiramate may help reduce cocaine use, cut cravings, and improve global functioning, new research suggests. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 28, 2013 Category: Consumer Health News Tags: Psychiatry News Source Type: news
New study shows promise for first effective medicine to treat cocaine dependence
(University of Maryland Medical Center) New research published in JAMA Psychiatry reveals that topiramate, a drug approved by the US Food and Drug Administration to treat epilepsy and migraine headaches, also could be the first reliable medication to help treat cocaine dependence. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - October 25, 2013 Category: Global & Universal Source Type: news
New Trial Started on Topamax Birth Defects: Now, AttorneyOne Can...
As Businessweek published on October 15, a new trial started alleging that the plaintiff's son was born with birth defects resulting from her use of Topamax. In light of this news, AttorneyOne, a...(PRWeb October 21, 2013)Read the full story at http://www.prweb.com/releases/2013/10/prweb11249477.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 23, 2013 Category: Pharmaceuticals Source Type: news
Lawsuit Calls Janssen's Topamax a "Pharmaceutical Equivalent of a Drive-by Shooting”
A Pennsylvania mother blames Topamax for her son’s cleft palate and lip and claims Johnson & Johnson’s Janssen Pharmaceuticals negligently failed to inform patients about its risks until the FDA ordered stronger warnings in 2011. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 16, 2013 Category: Pharmaceuticals Source Type: news
Trokendi XR (Topiramate Extended-release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 9, 2013 Category: Drugs & Pharmacology Source Type: news
Use of Topiramate in Preventing Pediatric MigraineUse of Topiramate in Preventing Pediatric Migraine
Topiramate has shown promise as a means of preventing migraines in the pediatric population. Pediatric Pharmacotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2013 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news
Topamax / Topiramate Drug Profile
Topamax - generic topiramate - is an anticonvulsant approved for use in treating epilepsy and migraine headaches. It is also frequently prescribed off-label for bipolar disorder. Information on uses, major warnings, and the effectiveness of Topamax for weight loss. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - September 3, 2013 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news
Diet drug controversy as US approves meds rejected by Europe
The decision from the Food and Drug Administration (FDA) to allow two anti-obesity drugs to be marketed in the US has been called into question by a senior doctor publishing in the BMJ. Dr. Sidney Wolfe, founder of the health research group at Public Citizen, says that the fact these drugs have been banned by the European regulator "puts the FDA to shame." Belviq (lorcaserin) and Qsymia (phentermine plus topiramate) are available as anti-obesity drugs in the US... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 23, 2013 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news
